novartis glp 1 drug Novo's Wegovy becomes first GLP-1 approved for MASH 15 Surprising Benefits of GLP-1

Suspected adverse reactions should be reported via the Yellow Card Scheme (yellowcard.mhra.gov.uk or the Yellow Card app)

Epidermal insulin resistance as a therapeutic target in acanthosis nigricans

By Distribution Channel)- Global Market Size, Share, Growth, Trends, Statistics Analysis Report, By Region And Segment Forecasts 20242032 Market Overview The glucagon-like peptide 1 (GLP-1) agonist market size was valued at USD 10.8 Billion in 2023 and is expected to reach a market size of USD 21.2 Billion by 2032 at a CAGR of 7.8%

He W, Wang H, Zhao C, Tian X, Li L, Wang H

MASH Treatment# Recommendation : Survodutide Reason : FDA Breakthrough Therapy Designation (higher than pemvidutide's Fast Track), 62% MASH resolution in Phase 2, and dedicated Phase 3 LIVERAGE trials specifically designed for MASH with fibrosis

Nevertheless, GLP1RAs did not statistically significantly improve systolic function, as demonstrated by Kumarathurai et al